SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TOSHI

TOSHI.X is trending as the community anticipates potential exchange listings and discusses its position as a leading meme coin on the Base network. Bullish sentiment is fueled by mentions of possible partnerships and the expectation of significant gains, though some traders advise caution and profit-taking. The coin's performance is being closely watched in relation to broader market trends and potential rate cuts.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is trending amid speculation about potential government contracts, fueled by recent institutional buying and a Congress member's disclosed stock purchase. The community is actively discussing the possibility of a short squeeze, citing high short interest and heavy call option flow. BBAI's association with AI and government contracts, especially in defense, remains a key talking point.

Shineco, Inc. is a holding company, which through its subsidiaries, engages in the production and distribution of plant-based products. It operates through the following segments: Rapid Diagnostic and Other, Other Agricultural, and Healthy Meals Products. The Rapid Diagnostic and Other Products segment is conducted through Biowin, which specializes in the development, production and distribution of innovative rapid diagnostic products and related medical devices for the most common diseases. The Other Agricultural Products segment is conducted through Wintus, which specializes in producing, processing and distribution of agricultural products, such as silk and silk fabrics as well as trading of fresh fruit. The Healthy Meals Products segment is conducted through Fuzhou Meida, which specializes in developing healthy meals for people with slow metabolic health and those in recovery from metabolic disorders. The company was founded on August 20, 1997 and is headquartered in Beijing, China.

Shineco Inc

SISI is trending as traders discuss its potential, referencing 

Presidio Property Trust, Inc. is a self-managed real estate investment trust, which invests in a diverse multi-tenant portfolio of real estate assets. It operates through the following segments: Office and Industrial Properties, Model Home Properties, and Retail Properties. The Office and Industrial Properties segment consists of office buildings and an industrial property leased to a variety of tenants ranging from small businesses to large public companies. The Model Home Properties segment consists of model home residential properties leased to homebuilders. The Retail Properties segment includes shopping centers. The company was founded by Jack Kendrick Heilbron on September 28, 1999 and is headquartered in San Diego, CA.

Presidio Property Trust Inc - Ordinary Shares - Class A

Fueled by a low float and a prior reverse split, $SQFT is experiencing significant volatility and trending upwards, leading to discussions around short squeezes and potential price targets. Community members are actively debating whether the surge is sustainable or a pump and dump, with some pointing to a recent offering and others emphasizing technical indicators. The stock's unusual price action is attracting both bullish and bearish sentiment, with traders closely monitoring key levels for potential breakouts or pullbacks.

MicroAlgo, Inc. operates as a holding company, which engages in the development and application of bespoke central processing algorithms. Its services include algorithm optimization, accelerating computing power without the need for hardware upgrades, lightweight data processing, and data intelligence. The company was founded May 14, 2018 and is headquartered in New York, NY.

MicroAlgo Inc

MLGO is trending as traders discuss its potential for a short squeeze and compare it to other recently volatile stocks. Community members are debating its valuation, potential for high percentage gains, and upcoming financial reports. Some investors are closely monitoring the stock's price action and volume, anticipating a significant move.

Alibaba Group Holding Ltd. engages in providing technology infrastructure and marketing reach. It operates through the following business segments: China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others segments. The Core Commerce segment consists of platforms operating in retail and wholesale. The China Commerce segment includes China commerce retail and wholesale businesses. The International Commerce segment focuses on international commerce retail and wholesale businesses. The Local Consumer Services segment is involved in To-Home businesses, which include Ele.me, local services and delivery platform, and Taoxianda, and To-Destination segment businesses which include Amap, the provider of mobile digital map, navigation and real-time traffic information, and restaurant and local services guide platform. The Cainiao segment has Cainiao Network and offers domestic and international one-stop-shop logistics services and supply chain management solution. The Cloud segment includes Alibaba Cloud and DingTalk. The company was founded by Chung Tsai and Yun Ma on June 28, 1999 and is headquartered in Hangzhou, China.

Alibaba Group Holding Ltd - ADR

Alibaba Group Holding Ltd

Alibaba is trending as positive sentiment builds around the company's AI and cloud computing initiatives, including reports of using internally designed chips, which has spurred analysts to raise price targets. Community members are discussing whether this rally has legs, with some highlighting the stock's breakout potential after a period of consolidation, while others expressing caution about short-term overextension. The stock is viewed by some as undervalued compared to its US counterparts, fueling optimism about future growth.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global is trending as investors discuss its potential amidst AI enthusiasm and debate its valuation. Community members are focused on the stock's repeated rejections at the $20 mark, questioning its ability to break through. Discussions also include the upcoming Zeta Live event and its potential impact on the stock's price, with some anticipating new product announcements.

Amprius Technologies, Inc. engages in the development, manufacture, and market lithium-ion batteries for mobility applications, including the aviation, electric vehicle and light electric vehicle industries. It operates through the United States and Rest of the World geographical segments. The company was founded by Mark C. Platshon in 2008 and headquartered in Fremont, CA.

Amprius Technologies Inc

Amprius Technologies is trending due to a repeat $35 million purchase order for its SiCore batteries from a leading UAS manufacturer, signaling growing demand in the drone sector. Community discussions highlight the company's best-in-class battery technology already in production, potential for further upside, and comparisons to competitors like $ENVX. Bullish sentiment also revolves around domestic battery production and potential benefits from tax credits, as well as possible partnerships within the drone industry.

Upstart Holdings, Inc. engages in the provision of a cloud-based artificial intelligence lending platform. It operates through the following segments: Personal Lending, Auto Lending, and Other. The Personal Lending segment focuses on unsecured personal loans and small dollar loans. The Auto Lending segment is involved in auto refinance and auto retail loans. The Other segment refers to HELOCs and other. The company was founded by David Joseph Girouard, Anna Mongayt Counselman, and Paul Gu in December 2013 and is headquartered in San Mateo, CA.

Upstart Holdings Inc

Upstart is trending as discussions revolve around potential benefits from anticipated rate cuts and the company's AI-driven lending model. Community members are analyzing Elliott Wave patterns, identifying potential entry points, and speculating on price movements, especially with the upcoming FOMC meeting. Some investors are comparing UPST to peers, noting its potential for growth and profitability in a favorable market environment.

Ginkgo Bioworks Holdings, Inc. is a biotech company. Its platform enables biotechnology applications across diverse markets, from food, agriculture, industrial chemicals, and pharmaceuticals. It operates through the Cell Engineering and Biosecurity segments. The Cell Engineering segment consists of end-to-end cell engineering solutions and cell engineering tools offerings for biological research and development. The Biosecurity segment focuses on biomonitoring and bioinformatics support services, offered to both government and non-government customers through the company's two core offerings, Canopy and Horizon. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.

Ginkgo Bioworks Holdings Inc - Ordinary Shares - Class A

Ginkgo Bioworks ($DNA) is trending amid discussions around potential catalysts, including biosecurity initiatives and partnerships with pharmaceutical giants like Eli Lilly and Novo Nordisk, aimed at boosting production and developing new therapies. Community members are actively debating the company's long-term strategy, insider trading activity, and potential for a short squeeze, influenced by reports on institutional ownership and AI-driven advancements. The stock is further influenced by broader market trends, such as potential shifts in US-China relations and regulatory changes impacting the biotech sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

VF Corp (VFC) announced on Monday that they have entered into a definitive agreement for Bluestar Alliance to acquire the Dickies brand for $600 million in cash.The company said that the transaction is expected to close by the end of calendar year 2025. Shares of VF Corp traded over 2% higher in Monday’s pre-market session.Retail sentiment on <a href="https://stocktwits.com/symbol/VFC">VF Corp</a> remained unchanged in the ‘bearish’ territory, with message volumes at ‘normal’ levels, according to data from Stocktwits.Dickies&nbsp;is an American brand that offers clothing primarily in the workwear and streetwear categories, with distribution in 55 countries. “Since 1922, Dickies&nbsp;has provided hard-wearing, long-lasting and comfortable clothes, cementing its status as a storied brand in performance workwear,” said Joseph Gabbay, CEO of Bluestar Alliance, a brand management firm.VF Corp’s CEO Bracken Darrell said he was “confident” that under Bluestar Alliance’s ownership, Dickies will continue to improve and realize its significant growth potential. “As I’ve said before, we continuously evaluate our portfolio and this transaction will enable us to bring our net debt level down and will be accretive to our growth on a pro-forma basis,” Darrell said.VF Corp has been undergoing a turnaround under Darrell, with the company having trimmed jobs and also looking to reduce costs by selling some brands. It is also seeing costs related to the Trump administration’s tariffs on global trading partners. In July, the company noted that the incremental annualized tariff impact would be between $100 million and $120 million, down from its prior estimate of $150 million.Shares of VF Corp have declined nearly 31% this year and have fallen over 18% in the last 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-shares-surge-elon-musk-purchases-stock-first-time-since-2020/chwwIvpRdUG">Tesla Shares Surge As Elon Musk Discloses First Stock Purchase In Open Market Since 2020: Report</a>

In this photo illustration, the VF Corporation company logo is seen displayed on a smartphone screen.

VF Corp To Sell Dickies Brand To Bluestar Alliance For $600M

VF Corp said that the transaction is expected to close by the end of calendar year 2025.

Equity

The Campbell’s Company (CPB) experienced multiple price target hikes from Wall Street on Thursday, with TD Cowen citing that the packaged food maker’s annual profit guidance was less negative than initially feared, due to an acceleration of cost savings and near-term tariff mitigation.TD Cowen raised its price target to $31 from $29 and maintained a ‘Hold’ rating, according to TheFly. The firm added that the company’s fourth-quarter results were all better than expected.Retail sentiment on <a href="https://stocktwits.com/symbol/CPB">Campbell’s</a> remained unchanged in the ‘bullish’ territory, with chatter at ‘extremely high’ levels, according to data from Stocktwits. The retail user message count on the stock jumped 175% in the last 24 hours, as of Thursday morning, and shares of the firm were down nearly 3% during midday trading.<figure class="image"><img style="aspect-ratio:806/96;" src="https://news.stocktwits-cdn.com/CPB_sentiment_png_a93adb3d63.webp" alt="CPB sentiment.png" width="806" height="96"><figcaption>CPB sentiment and message volume September 4, 2025, as of 1:50 pm ET | Source: Stocktwits</figcaption></figure>Bernstein also raised its price target on Campbell's to $39 from $38 and kept an ‘Outperform’ rating. The firm noted that Campbell's seems to be doing the right things to get the portfolio moving again, investing in brand support and innovation, and fueling these investments with stepped-up productivity improvements.On Wednesday, CEO Mick Beekhuizen stated that consumers remain cautious and are being intentional with their spending, a trend that is expected to persist amid price increases resulting from the Trump administration’s tariffs, which are anticipated to slow demand for goods across the discretionary and consumables categories.Bernstein added that while snack category dynamics remain sluggish, management expects this portfolio to stabilize by the second half of 2026, noting that it's encouraging to see the recent success of more premium products, such as Milano cookies.Campbell’s shares have declined nearly 22% this year and fallen over 36% in the last 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/giii-apparel-ceo-says-company-absorbing-some-tariff-costs/chwdfxyRdYz">G-III Apparel CEO Says Company Absorbing Some Tariff Costs To Stay Competitive, Gain Market Share</a>

Prego brand spaghetti sauce in glass jars. (Source: Getty Images)

Campbell’s Gains Wall Street Confidence With Multiple Price Target Hikes, Retail Chatter Surges

Bernstein raised its price target on Campbell's to $39 from $38 and noted that the company appears to be taking the right steps to revitalize the portfolio, investing in brand support and innovation.

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) on Wednesday said that it has approved Biogen Inc.’s (BIIB) Zuranolone to treat moderate or severe postnatal depression (PPD) in adults following childbirth.Postnatal depression is a type of depression that many parents experience after having a baby and is marked by feelings of sadness, irritability, anxiety, loss of interest, extreme fatigue, appetite changes, among others. One in every ten women is affected by postnatal depression within a year of childbirth, as <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.gov.uk/government/news/mhra-approves-zuranolone-to-treat-postnatal-depression-in-adults-following-childbirth">per </a>MHRA.Biogen’s Zuranolone, under the brand name Zurzuvae, is the first oral treatment for postnatal depression approved in the UK, the agency said.The drug comes as a capsule and should be taken orally at night with a fat-containing meal for 14 days. Common side effects of the medicine include memory impairment, confusion, and fatigue, among others.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/BIIB">BIIB stock</a> trended within the ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended marketing authorization for Zurzuvae last month in the European Union. The drug was approved by the U.S. Food and Drug Administration in 2023. According to Biogen, an estimated 5-20% of women with a pregnancy experience symptoms of PPD in Europe.Zurzuvae was discovered by Sage Therapeutics Inc. (SAGE). In 2020, Biogen and Sage Therapeutics entered into a collaboration to jointly develop and commercialize Zurzuvae in the U.S. As part of the agreement, Biogen received exclusive rights to develop and commercialize Zurzuvae outside of the U.S., excluding Japan, Taiwan, and South Korea.In the second quarter, Biogen reported revenue of $46.4 million from Zurzuvae, up from $14.9 million in the corresponding quarter of 2024, driven by increased demand.BIIB stock is down by 10% this year and by about 32% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-suncar-technology-stock-rallying-today/chsUeO7RdlB">Why Is SunCar Technology Stock Rallying Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration the logo of Biogen is seen on a smartphone with the FDA logo in the background. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)  

UK Regulator Approves Biogen’s Drug For Treating Postnatal Depression

Zuranolone is the first oral treatment for postnatal depression approved in the UK, the agency said. 

Sarepta Therapeutics, Inc. (SRPT) announced on Thursday that it has entered into agreements with investors to restructure about $700 million of debt.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-refinancing-approximately-700">said</a> it will exchange approximately $700 million in aggregate principal amount of its existing convertible notes due 2027 for roughly $602 million in new 4.875% convertible senior notes due 2030, up to approximately 6.7 million shares of its common stock, and about $123.3 million in cash.Although the company has managed to push back the maturity of the new debt to 2030, it is also offering cash and common stock to investors. A fear of a potential dilution appears to have disappointed investors. SRPT stock was down over 7% at the time of writing.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SRPT">SRPT stock</a> stayed within ‘neutral’ territory over the past 24 hours, while message volume remained at ‘low’ levels. The stock is among the top ten trending names on the platform.<figure class="image"><img style="aspect-ratio:569/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_21_at_10_26_20_AM_png_8591ecfd20.webp" alt="Screenshot 2025-08-21 at 10.26.20 AM.png" width="569" height="62"><figcaption>SRPT's Sentiment Meter and Message Volume as of 10:26 a.m. ET on Aug. 21, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed optimism about the refinancing.<stembedurl>https://stocktwits.com/scaredmoneymakenomoney/message/626069691</stembedurl>CEO Doug Ingram said that the exchange marks an important progress in the company’s long-term financial strategy. "By extending the maturity of a meaningful portion of our convertible notes to 2030, we have completed a shareholder-friendly transaction that significantly enhances our balance sheet flexibility and strengthens our financial position,” Ingram said.Ingram also said that the company believes it is well-positioned to fully fund its pipeline and meet its near-term obligations.Bank of America said that the debt refinancing transaction "makes sense" as it helps mitigate some near-term concerns about the company's ability to meet its obligations. Still, the firm continues to think clarity on uptake of Elevidys from here will be needed to get more comfortable with the long-term outlook.Sarepta’s gene therapy, Elevidys, a medicine intended for the treatment of Duchenne muscular dystrophy (DMD), created safety concerns following the death of two patients after treatment earlier this year. Both non-ambulatory patients suffered from acute liver failure.Sarepta has now resumed shipments for ambulatory individuals after a temporary pause initiated in late July. The company is now working with the FDA on the safety labelling process and risk-mitigation approach for non-ambulatory individuals. Citi on Wednesday <a href="https://stocktwits.com/news-articles/markets/equity/citi-believes-fda-may-closely-watch-sarepta-safeguards-for-gene-therapy-in-non-ambulatory-dmd-patients/chsiUM2RdLP">said</a> that the U.S. Food and Drug Administration may take a “more comprehensive look” at the regimen devised by Sarepta for non-ambulatory patients.Last month, the company said that it had initiated immediate changes to reduce operating expenses, including a 36% workforce reduction and pipeline reprioritization, in a bid to meet its 2027 financial obligations.Following the crisis with the gene therapy, Sarepta also <a href="https://stocktwits.com/news-articles/markets/equity/analyst-says-sarepta-lost-credibility-by-exiting-arrowhead-at-a-loss/chsRn7vRdON">unwound</a> its equity position in Arrowhead Pharmaceuticals earlier this month, in less than a year of its investment.SRPT stock is down by 84% this year and by about 87% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/j-and-j-to-invest-2-billion-to-expand-manufacturing-in-north-carolina/chsSyKYRdig">This Pharma Giant Is Set To Invest $2B To Expand Manufacturing In North Carolina, And It Just Received A Price Target Hike From Citi: Do You Own It?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Sarepta Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Sarepta Just Got A Good Restructuring Deal For $700M Debt, But Stock Tumbles 7% – Here’s Why

Although the company has managed to push back the maturity of the new debt to 2030, it is also offering cash and common stock to certain investors as part of the deal.

Truist on Monday lowered its price target on Regeneron (REGN) to $812 from $940, citing concerns with the company’s Eylea drug. The firm, however, kept a ‘Buy’ rating on the shares.The near-term investor focus remains on Eylea and Eylea HD uptake, though Regeneron continues to deliver growth on its top and bottom line with Dupixent and Libtayo programs, the analyst told investors in a research note. On Stocktwits, retail sentiment around the stock trended in the ‘bearish’ territory over the past 24 hours, coupled with ‘low’ message volume.<figure class="image"><img style="aspect-ratio:1398/126;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_11_at_1_26_40_PM_png_155e98c160.webp" alt="REGN's Sentiment Meter and Message Volume as of 1:26 p.m. ET on Aug. 11, 2025 | Source: Stocktwits" width="1398" height="126"><figcaption>REGN's Sentiment Meter and Message Volume as of 1:26 p.m. ET on Aug. 11, 2025 | Source: Stocktwits</figcaption></figure> A user further opined that the range of $400-$450 is a good entry point for the stock.<stembedurl>https://stocktwits.com/Johny34211/message/624597691</stembedurl>Eylea is approved to treat vision-threatening conditions that impact patients, such as diabetic retinopathy (DR), macular edema following retinal vein occlusion (RVO), and wet age-related macular degeneration (wAMD). Eylea HD, meanwhile, is a version of the drug that requires fewer injections.<a href="https://stocktwits.com/symbol/REGN">Regeneron</a> maintains exclusive rights to Eylea and Eylea HD in the U.S. Bayer has licensed the exclusive marketing rights outside of the U.S., where the companies share equally the profits from sales of the two products. In the second quarter, total Eylea U.S. net sales decreased 25% to $1.15 billion, while Eylea HD U.S. net sales increased 29%.The company also said that it expects its regulatory approvals to be delayed for its currently pending U.S. Food and Drug Administration applications for Eylea HD, which were supposed to be decided on by August 2025.The anticipated delay, the company said, is related to observations from an FDA general site inspection at the filler for Eylea HD in these regulatory applications, Catalent Indiana LLC. This inspection was completed in mid-July and was not specific to Eylea HD. Novo Nordisk recently acquired Catalent.The company, however, expressed optimism for a quick resolution of the filling issues for Eylea HD, citing its progress with alternate third-party fillers and Novo Nordisk’s communications with the FDA.According to data from Koyfin, 16 of 24 analysts covering Regeneron rate it ‘Buy’ or higher, while seven rate it a ‘Hold,’ and one rates it a ‘Strong Sell.’The stock has an average price target of $708.91, representing an upside of about 28%.REGN stock is down by 22% this year and by about 51% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/novartis-drug-shows-improvement-in-sjogrens-disease-in-late-stage-trials/chrH2PLRde0">Novartis Drug Shows Improvement In Sjögren's Disease In Late-Stage Trials: Analyst Deems Data Positive For Zura Bio As Well</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Regeneron Pharmaceuticals company logo is displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

This Stock Has Tumbled 50% In One Year, Gets A Price Target Cut Today – But Retail Believes $400-450 Is A Good Entry Point

Truist, however, kept a ‘Buy’ rating on the shares.

Wells Fargo on Thursday raised its price target on Sarepta Therapeutics, Inc. (SRPT) to $50 from $48 after the company’s second-quarter earnings beat Wall Street expectations on Wednesday.Wells’ new price target of $50 implies nearly 208% upside potential from the stock’s closing price on Wednesday. The analyst kept an ‘Overweight’ rating on the shares.The firm reiterated its confidence in the Elevidys franchise, noting that it sees an intact benefit-risk for ambulatory patients and potential upside from future updates on the non-ambulatory side.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SRPT">Sarepta</a> remained unmoved within ‘neutral’ territory over the past 24 hours while message volume remained at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:627/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_07_at_11_16_43_AM_png_bbc7e903bf.webp" alt="SRPT's Sentiment Meter and Message Volume as of 11:15 a.m. ET on Aug. 7, 2025 | Source: Stocktwits" width="627" height="64"><figcaption>SRPT's Sentiment Meter and Message Volume as of 11:15 a.m. ET on Aug. 7, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that the second-quarter sales number shows that the recent patient deaths did not undermine demand.<stembedurl>https://stocktwits.com/parbv/message/624138164</stembedurl>Another highlighted that Elevidys caters to a niche patient population not addressed by many others.<stembedurl>https://stocktwits.com/Bearcase/message/624132232</stembedurl>Sarepta’s gene therapy, Elevidys, a medicine intended for the treatment of Duchenne muscular dystrophy (DMD), created safety concerns following the death of two patients after treatment. Both non-ambulatory patients suffered from acute liver failure.Duchenne Muscular Dystrophy is a genetic disorder characterized by progressive weakness and chronic inflammation of the skeletal, heart, and respiratory muscles. The disease primarily impacts boys.Sarepta has now resumed shipments for ambulatory individuals after a temporary pause initiated in late July. The company is now working with the FDA on the safety labelling process and risk-mitigation approach for non-ambulatory individuals, CEO Doug Ingram said on Wednesday.For the second quarter, Sarepta reported total revenues of $611.1 million, above an analyst estimate of $531.04 million, owing to higher net product revenue of Elevidys. Adjusted and diluted earnings per share came in at $2.02, up from $0.43 in the corresponding quarter of 2024, and above an analyst estimate of $0.67.The company also said that it is on track to realize over $100 million in cost savings through the end of 2025 as part of the restructuring announced in July. SRPT stock is down by about 86% this year and by about 87% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/duolingo-stock-rockets-30-percent/chrm761Rd37">Duolingo Stock Rockets 30% And Retail Chatter Surges A Whopping 1,400% In 24 Hours: Here’s Why</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

This Pharma Stock Shot Up 8% Today, Gets A Price Target Hike From Wells Fargo: Here’s Why Retail Sees Opportunity

Wells’ new price target of $50 implies nearly 208% upside potential from the stock’s closing price on Wednesday. 

Sarepta Gets A Price Target Hike From Wells Fargo: Retail Highlights Consistent Demand For Elevidys

Shares of Sarepta Therapeutics Inc. (SRPT) traded 20% higher on Tuesday afternoon after the U.S. Food and Drug Administration (FDA) allowed the company to resume shipping Elevidys, its gene therapy for Duchenne muscular dystrophy, to children who are still able to walk.Elevidys is the first and only gene therapy approved in the U.S. for Duchenne muscular dystrophy, a rare and progressive condition that affects mainly boys and leads to loss of muscle function.Sarepta has been in a quagmire ever since the company reported the deaths of two patients treated with Elevidys from liver failure earlier this year.Sarepta had paused Elevidys' shipments last week to allow the FDA to complete a review of available safety information. The company is still in discussions with the FDA regarding an updated safety labeling on Elevidys. The pause on Elevidys for patients who cannot walk continues as the discussions linger on.On Monday, the company said that the death of an 8-year-old boy in Brazil was deemed unrelated to treatment with Elevidys by the FDA.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SRPT">SRPT</a> is trending in the ‘extremely bullish’ territory, while message volume jumped from ‘high’ to ‘extremely high’ levels over the past 24 hours.<figure class="image"><img style="aspect-ratio:1354/132;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_29_at_2_20_10_PM_png_e1c2ee7b01.webp" alt="SRPT's Sentiment Meter and Message Volume as of 2:30 p.m. ET on July 29, 2025 | Source: Stocktwits" width="1354" height="132"><figcaption>SRPT's Sentiment Meter and Message Volume as of 2:30 p.m. ET on July 29, 2025 | Source: Stocktwits</figcaption></figure>After the hold was lifted on Monday, several analysts expressed relief or more concerns. &nbsp;JPMorgan upgraded Sarepta to ‘Neutral’ from ‘Underweight’ with a $24 price target. The FDA's recommendation to remove the voluntary pause of shipments of Elevidys in ambulatory patients is a "clear win" for the company, the analyst said.Bernstein, meanwhile, believes "it is only a matter of time before we learn of a death in an ambulatory patient that is deemed to be Elevidys-related."BMO Capital noted that while the financial overhang is partially removed with the lift of the hold, it expects a certain "hesitancy" from physicians and patients for Elevidys treatment in the near term.Barclays analyst Gena Wang, meanwhile, upgraded Sarepta to ‘Equal Weight’ from ‘Underweight’ with a price target of $22, up from $10. The suspension removal "removes the worst-case scenario" of a sustained period of Elevidys being off the market, and major liquidity risk is removed for now, it said, while adding that it is looking at greater FDA clarity.SRPT stock is down by 86% this year and by about 89% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/lucid-signs-up-timothee-chalamet-as-global-brand-ambassador/choaPQFR5yV">Lucid Signs Up Timothée Chalamet As Global Brand Ambassador: Retail Terms It A Desperate Cash-Draining Move</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Did Sarepta Stock Jump 20% On Tuesday? Here’s What JPMorgan, Bernstein, Barclays Said About Elevidys

JPMorgan upgraded Sarepta to ‘Neutral’ from ‘Underweight’ with a $24 price target.

Shares of Sarepta Therapeutics (SRPT) tumbled 14% on Friday after a patient reportedly died following treatment with one of the firm’s gene therapies, drawing concerns from Wall Street analysts.A company spokesperson <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-07-18/sarepta-says-another-patient-died-after-receiving-gene-therapy">told</a> Bloomberg that a 51-year-old patient died of acute liver failure last month in an early-stage trial of a gene therapy to treat limb-girdle muscular dystrophy. Limb-girdle muscular dystrophy (LGMD) is a group of genetic conditions causing progressive muscle weakness and wasting, primarily affecting the muscles around the shoulders and hips.The company is already under pressure following the death of two patients following treatment with its gene therapy for Duchenne Muscular Dystrophy called Elevidys earlier this year.Following the news, Morgan Stanley analyst Michael Ulz said that the news adds to the ongoing safety concerns and near-term uncertainty around <a href="https://stocktwits.com/symbol/SRPT">Sarepta</a>.Leerink, meanwhile, opined that Sarepta management, knowing of a limb-girdle muscular dystrophy patient death in the trial and not disclosing it when announcing a restructuring earlier this week, is "deeply troubling and further undermines credibility."The firm added that it is “deeply disappointed in management's repeated execution missteps."While this is the first patient death reported in a limb-girdle muscular dystrophy trial, it is the third death reported by Sarepta this year across its gene therapy programs, William Blair told investors in a research note. Blair pointed out that Sarepta did not disclose the third patient death in its recent business update, which it termed "unfortunate and concerning.”Last month, the U.S. Food and Drug Administration said that it is probing the death of two pediatric patients with Duchenne Muscular Dystrophy (DMD) following treatment with Elevidys. The agency said it is investigating the risk of acute liver failure with serious outcomes, including hospitalization and death, following Elevidys and is evaluating the need for further regulatory action.Earlier this week, the company announced that it would eliminate 500 jobs, or approximately 36% of its workforce, as part of a restructuring effort aimed at achieving $400 million in annual cost savings. Sarepta also stated that it has agreed to the FDA’s request to include a black box warning in the ELEVIDYS label for acute liver injury and acute liver failure, to address the agency’s concerns regarding the use of the therapy in DMD patients who can walk.The company has halted shipments of the therapy to patients who cannot walk and is in talks with the FDA regarding a possible resumption.On Stocktwits, retail sentiment regarding Sarepta is trending in “extremely bullish” territory at the time of writing, accompanied by “extremely high” message volume.<figure class="image"><img style="aspect-ratio:628/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_18_at_10_54_58_AM_png_8b22d77332.webp" alt="SRPT's Sentiment Meter and Message Volume as of 10:55 a.m. ET on July 18, 2025 | Source: Stocktwits" width="628" height="63"><figcaption>SRPT's Sentiment Meter and Message Volume as of 10:55 a.m. ET on July 18, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that the company destroyed the possibility of profitability or partnerships with the recent news.<stembedurl>https://stocktwits.com/Daily_Trader87/message/621494983</stembedurl>SRPT stock is down over 85% this year and by 87% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/retail-chatter-on-bmy-doubles-in-24-hours-with-drug-failing-to-meet-primary-goal/ch8kA37R5qZ">Retail Chatter On BMY Doubles In 24 Hours With Drug Failing To Meet Primary Goal: Here's What Investors Are Thinking</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Sarepta Draws Wall Street Ire After Third Patient Death This Year: Analyst Says ‘Deeply Concerning’ The Incident Wasn’t Reported Earlier 

A company spokesperson told Bloomberg that a 51-year-old patient died of acute liver failure last month in an early-stage trial of a gene therapy to treat limb-girdle muscular dystrophy.

Regeneron Pharmaceuticals, Inc. (REGN) on Wednesday announced that the U.S. Food and Drug Administration has granted accelerated approval for its Lynozyfic to treat adult patients with relapsed or refractory (R/R) multiple myeloma.The drug is now <a target="_blank" rel="noopener noreferrer nofollow" href="https://newsroom.regeneron.com/news-releases/news-release-details/lynozyfictm-linvoseltamab-gcpt-receives-fda-accelerated-approval">approved</a> in the U.S. for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti‑CD38 monoclonal antibody.Multiple myeloma is the second most common blood cancer. According to Regeneron, there are over 187,000 new cases of the cancer diagnosed globally every year, with more than 36,000 diagnosed and 12,000 deaths anticipated in the U.S. in 2025.The disease is characterized by the proliferation of cancerous plasma cells that crowd out healthy blood cells in the bone marrow, infiltrate other tissues, and cause potentially life-threatening organ injury.Shares of <a href="https://stocktwits.com/symbol/REGN">Regeneron</a> jumped 2% on Wednesday afternoon.While Lynozyfic was granted accelerated approval based on the LINKER-MM1 trial in which patients experienced a 70% objective response rate, continued approval may depend upon verification and description of clinical benefit in a confirmatory trial, the company said.George D. Yancopoulos, Chief Scientific Officer of Regeneron, said that the company is advancing its program for Lynozyfic, exploring its use in earlier lines of treatment as monotherapy and in novel combinations.On Stocktwits, retail sentiment around Regeneron is trending in the ‘bearish’ territory over the past 24 hours while message volume remained at ‘low’ levels.<figure class="image"><img style="aspect-ratio:625/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_02_130755_png_5f1153bfc5.webp" alt="REGN's Sentiment Meter and Message Volume as of 1:05 p.m. ET on July 2, 2025 | Source: Stocktwits" width="625" height="60"><figcaption>REGN's Sentiment Meter and Message Volume as of 1:05 p.m. ET on July 2, 2025 | Source: Stocktwits</figcaption></figure>REGN stock is down by 23% this year and by about 48% over the past 12 months. &nbsp;Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/organon-stops-drug-development-for-endometriosis-pain-after-mid-stage-trial-fails/chF0qINRT60">Organon Drops Drug Development For Endometriosis Pain After Mid-Stage Study Fails To Show Results</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Regeneron’s Therapy For Blood Cancer Bags FDA Approval: REGN Stock Jumps

While Lynozyfic was granted accelerated approval based on response rate in the LINKER-MM1 trial, continued approval may depend upon verification and description of clinical benefit in a confirmatory trial, the company said.

Advisorshares Trust - AdvisorShares Dorsey Wright Short ETF -1x Shares

Cut 25 bps

Cut 50+ bps

No change

Hike 25 bps

It’s Fed Decision Week. Polymarket gives a 90% chance of a 25 bps cut. What’s your call? 
 
*Powered by Polymarket

DWSH
AdvisorShares Dorsey Wright Short ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest DWSH News

DWSH AdvisorShares Dorsey Wright Short ETF